Why Insurance Matters for Psychedelic Therapy
Lia Mix and Britt Rollins discuss insurance, infrastructure, and what it will take to scale psychedelic care safely.
delphiwp
Advancing Federal Psychedelic Policy
Welcome and Introduction of Melissa Lavasani Lia Mix: Hello, everyone, and welcome. I am Lia Mix, the CEO of Delphi, and we are excited to have you for our monthly insight session. Today, we welcome Melissa Lavasani, the founder and CEO of the Psychedelic Medicine Coalition (PMC). PMC is the only Washington, D.C.-based nonprofit dedicated to advancing psychedelic-assisted therapies at the federal level. A nationally recognized policy leader, Melissa authored and led the passage of Washington, D.C.’s Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020. This passed with 76 percent voter approval, motivated by her personal experience using psychedelic medicines to recover from severe postpartum depression. Under her leadership, PMC has built bipartisan support in Congress and advanced key federal legislation through the Congressional Psychedelics Advancing Therapies (PATH) Caucus. This includes the Innovative Therapies Centers for Excellence Act and the Expanding Veterans Access to Emerging Treatments Act.
From Battlefield to Public Health Policy
In this Delphi Insight Session, Dr Leith States discusses psychedelic-assisted therapies and ibogaine and how they can impact public health.
Texas Ibogaine, Australia Veterans, and Freedom to Heal
This month, the strongest policy signal is that access is being built from multiple directions at once. Texas is using state dollars to stand up an ibogaine clinical trial consortium, federal lawmakers are trying to unlock a pre-approval access pathway for Schedule I psychedelics, and health systems abroad are moving from “permission” to “payment” with tighter delivery rules.
Operational Benchmarks for Psychedelic Care
December 2025’s studies add practical detail to a shift already underway: psychedelic care is moving from “can it work” to “how do we deliver it safely, consistently, and in a way payers can cover.”
Microdosing Shows Minimal Effects While Macrodose Studies Continue to Impress
November 2025 delivered a sharp reality check for psychedelic microdosing while macrodose studies advanced treatment options for depression, PTSD, and end-of-life distress.
Veterans, Microdosing, and Faster Psilocybin Timelines
Psychedelic Policy News from November 2025 where we cover veterans getting access, faster psilocybin approval, and micro(dosing) results.
Unlocking Safe Ibogaine Care
In this Delphi Insight Session, Lia Mix shares her journey with trauma and healing, and how Delphi and IHPI are advancing Ibogaine therapy.
Real-World Data Sharpen the Case for Safe and Effective Psychedelic Therapies
New psychedelic studies from October show 5-year safety data from esketamine, the importance of set & setting, and microdosing null-results.
New Psychedelic Studies Advance Clinical Applications
New psychedelic studies from September show psilocybin for addiction, LSD for anxiety, and group therapy for burnout, guiding clinical and policy integration.
